Mirvetuximab soravtansine
As of the edition of 20 October 2026, Mirvetuximab soravtansine is an antibody drug conjugate: marketed, first approved in 2022 (US); acts on FOLR1; US protection ends in 2034.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2025
- Kind
- Antibody drug conjugate
- Brand name
- Elahere
- First approved
- 14 November 2022 (US)
- Approvals on record
- 3 in 3 regions
- Holder of the most recent approval
- AbbVie; 3 holders in all
- Registered trials
- 28, 2 stopped early
- Disease areas
- Cancer; Pregnancy and women's health; Urinary and reproductive; Hormones; Skin and connective tissue; Digestive system
US protection
US protection ends in 2034.
US protection ends in 2034, computed as 12 years from the first US licence because FDA publishes no date for this product. The application that gives this date is held by ImmunoGen. The date is computed, not published.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product2 listings count towards this date. The exact date and each listing are in the product.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Mirvetuximab soravtansine.
Target
| Gene | Protein | UniProt |
|---|---|---|
| FOLR1 | Folate receptor alpha | P15328 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 1 | 0 |
| Phase 1 | 5 | 4 | 0 | 1 |
| Phase 2 | 17 | 3 | 13 | 1 |
| Phase 3 | 5 | 3 | 1 | 0 |
| All trials | 28 |